IN RE DATASCOPE CORP SECURITIES LITIGATION


\|

Keywords & Phrases

CaseNo: DC73788, CourtName: CLASS ACTION CASES, UniqueCaseRef: LCD>DC73788, Datascope, Fda, Stock, Datascope Common, Market, Proper, Shares, Expansion, Fraud, Exchange Act, Saper, Judgement, Prays, Sactioh, Purchase, Courses, Sty Procedures, Coiuiuoii Stock Price, Datascope Coiuiuoii Stock, Risk, Koncern, Life, Oonoerns, Tougher, Delay, Review, Sale, Ber , ContentID: 120249629

Case Documents

1993-11-05

COMPLAINT
[ see first page and extracted highlights below ] ItemID: 122432

22 pages
PDF

Total Documents: 1 document , 22 pages

Price: $ 19.95

IVESLCD01 KGI0001

1 . COMPLAINT

EXTRACTED KEY WORDS

FDA
STOCK
DATASCOPE COMMON
MEMBERS
MARKET
PROPER
SHARES
EXPANSION
FRAUD
EXCHANGE ACT
SAPER
JUDGEMENT
PRAYS
SACTIOH
PURCHASE
BUSINESS
COURSES
STY PROCEDURES
COIUIUOII STOCK PRICE
DATASCOPE COIUIUOII STOCK
RISK
KONCERN
LIFE
OONOERNS
TOUGHER
DELAY
REVIEW
SALE
BER

            FITZSIMMONS,                                                                RINGLE  -&
           Andrew  R.  Jacobs,                                                                 Esq.
             50  Park  Place,                                                              4th 
 I
            Newark,                                                 NJ  07102
               (201)  623-5,350                                                                    
            SCHOENGOLD  &  SPORN,  P.C.
            SaTnU81                                               P.  Sporn,                 Esq. 
           Joel  P.  Laitman,                                                                Esq. 
            233  Broadway
           New  York,  NY  10279
               (212)  964-0046
           Attorneys                                                           for  Plaintiff



                                                                                               IN 
         COURT
                                                                                                 


                                                                                                   
          ------------------"----------"----~~--,~-"------
                      MERRILL  ROTTER,  on  behalf..of                                             
ACTION  NO.
                       and  all                                           others            
                                              I

 SS  ACTIOV
                                                                                                   
PLAINT  FOR  VIOLATIONS  OF
                                                                                                   
TIONS  lo(b)            AND  20  OF  THE
                                                                                                   
URITIES  EXCHANGE  ACT  AND
                                                                                                   
PLEMENTAL  STATE  LAW
                                                                                 -against-         
IMS

                        DATASCOPE  CORP.  and  IMRENCE  SAPER,
                                                                                                   
            -" -__-__  --r-------------c-----
                                                                                                   


                                                               Plaintiff                   MERRILL 
leges         upon  knowledge
            with  respect                                                               to

SNIPPETS:

Seal would be brought to market in 18 months and September 1,

There are thousands of persons who are members of the

,device exemption from the FDA.

DataScope announced that the FDA had approved an eXpansiOn

scope announced that the FDA had approved an expansion of Clini-Y '

450,000 shares of Datascope common etook at $9.666 and 150,000

ber 3, 1992,, 300,000 shares at $29.625 per share and 300,000

day -- December 3, 1992 -- Saper earned a Q?&j,& of $12,062,890 from the sale of Datascope

_ review.

stated that the delay in VasoSeal was due to the "tougher regulaNow.16 '93 13:30

to oonoerns that VasoSeal posed the life